All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

citicoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	664	987-78-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: citicoline cytidine choline diphosphate cytidine diphosphate choline cytidine diphosphocholine cytidine diphosphorylcholine cytidoline difosfocin emicholine choline cytidine diphosphate citicholine citidoline corenalin cyscholin citicoline sodium	Donor of choline in biosynthesis of choline-containing phosphoglycerides. Molecular weight: 488.33 Formula: C14H26N4O11P2 CLOGP: -6.41 LIPINSKI: 1 HAC: 15 HDO: 4 TPSA: 213.50 ALOGS: -1.83 ROTB: 10

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70	33
kinase-selectivity-class	AXL,BRAF,CDK4,CDK9,EPHB4,ERBB2,GRK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,SYK,TEK,ZAP70	15
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	81.01	62.27	32	300	276421	90351694
Apraxia	75.56	62.27	12	320	2250	90625865
Neuroleptic malignant syndrome	75.13	62.27	16	316	15080	90613035
Perseveration	63.65	62.27	8	324	277	90627838

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood triglycerides increased	77.13	48.45	19	316	15877	42605123
Blood cholesterol increased	67.33	48.45	19	316	26722	42594278
Hyperglycaemia	57.22	48.45	19	316	45840	42575160
Hypertension	50.82	48.45	25	310	167179	42453821

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood triglycerides increased	76.96	42.65	20	721	23906	110564652
Apraxia	62.84	42.65	12	729	3528	110585030
Drug interaction	60.94	42.65	39	702	500144	110088414
Perseveration	55.53	42.65	8	733	419	110588139
Neuroleptic malignant syndrome	52.40	42.65	16	725	34043	110554515
Hyperglycaemia	48.42	42.65	19	722	85071	110503487
Hyperreflexia	45.84	42.65	11	730	9474	110579084

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06BX06	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Other psychostimulants and nootropics
MeSH PA	D018697	Nootropic Agents
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:39456	antiglaucoma drug
CHEBI has role	CHEBI:63726	neuroprotective agent
CHEBI has role	CHEBI:35476	antipsychotic agent

Related Drugs by ATC class:

N06BX Other psychostimulants and nootropics 19 drugs

acetylcarnitineadrafinilaniracetamcinnarizinedeanolfipexideidebenonelinopirdinemeclofenoxatenizofenoneoxiracetamphenibut show all 19 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.08	acidic
pKa2	11.57	acidic
pKa3	13.08	acidic
pKa4	4.04	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4029346	VUID
N0000180302	NUI
D00057	KEGG_DRUG
1099914	RXNORM
C0010725	UMLSCUI
CHEBI:16436	CHEBI
CHEMBL1256994	ChEMBL_ID
CHEMBL1231700	ChEMBL_ID
DB12153	DRUGBANK_ID
2290	INN_ID
33818-15-4	SECONDARY_CAS_RN
536BQ2JVC7	UNII
13804	PUBCHEM_CID
22451	MMSL
d05961	MMSL
004171	NDDF
009636	NDDF
1163164009	SNOMEDCT_US
1163165005	SNOMEDCT_US
698027009	SNOMEDCT_US
D003566	MESH_DESCRIPTOR_UI
CDC	PDB_CHEM_ID
4029346	VANDF

Pharmaceutical products:

None